Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin

Authors: Famke L. Schneiders, H. Pieter van den Berg, Godefridus J. Peters, Henk M. W. Verheul, Hans J. van der Vliet

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 58 year old woman with metastatic rectal carcinoma who developed severe gastrointestinal toxicity when the thusfar well-tolerated intravenous 5-fluorouracil (5-FU)/leucovorin containing chemotherapeutic regimen was replaced by the same chemotherapeutic regimen in combination with the oral 5-FU prodrug capecitabine. This increased toxicity is probably due to the intracellular retention of polyglutamated folates induced by prior leucovorin therapy which, upon subsequent administration of capecitabine, will result in an enhanced and prolonged inhibition of the, for DNA synthesis important, enzyme thymidylate synthase, essentially creating a situation equivalent to overdosing.
Literature
1.
go back to reference Van Cutsem E, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–106.PubMed Van Cutsem E, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–106.PubMed
2.
go back to reference Hoff PM, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282–92.PubMed Hoff PM, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282–92.PubMed
3.
go back to reference Punt CJ. Chemotherapy of patients with colorectal carcinoma. Ned Tijdschr Geneeskd. 2005;149:1441–7.PubMed Punt CJ. Chemotherapy of patients with colorectal carcinoma. Ned Tijdschr Geneeskd. 2005;149:1441–7.PubMed
4.
go back to reference Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRef Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRef
6.
go back to reference Cassidy J, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006–12.PubMedCrossRef Cassidy J, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006–12.PubMedCrossRef
7.
go back to reference Poole C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda®) in cancer patients. Cancer Chemother Pharmacol. 2002;49:225–34.PubMedCrossRef Poole C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda®) in cancer patients. Cancer Chemother Pharmacol. 2002;49:225–34.PubMedCrossRef
8.
go back to reference Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.PubMedCrossRef Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.PubMedCrossRef
9.
go back to reference Hennig IM, et al. Severe sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorin. J Clin Oncol. 2008;26:3411–7.PubMedCrossRef Hennig IM, et al. Severe sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorin. J Clin Oncol. 2008;26:3411–7.PubMedCrossRef
10.
go back to reference Cassidy J, et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res. 1998;4:2755–61.PubMed Cassidy J, et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res. 1998;4:2755–61.PubMed
11.
go back to reference Boarman DM, Allegra CJ. Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res. 1992;52:36–44.PubMed Boarman DM, Allegra CJ. Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res. 1992;52:36–44.PubMed
Metadata
Title
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin
Authors
Famke L. Schneiders
H. Pieter van den Berg
Godefridus J. Peters
Henk M. W. Verheul
Hans J. van der Vliet
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9598-9

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue